Author Archive | Raynovich Rod

What’s Up with the Biotech Rally?…Updates

buy accutane roche Update-2 1/21/19…Heads Up Red Futures Growth worries return-Asian Stocks down IMF Lowers Global Growth-Poor Performance for Europe Biotech rally could stall Update-1 1/20/19…XBI at $83.38 approaching November resistance at $85 Barron’s 2019 Roundtable biopharma picks: Abbvie (ABBV), Roche Holding (ROG), Gilead Sciences (GILD). ======= Biotech Rally Continues from the J.P.Morgan Healthcare Conference Slow and steady […]

Continue Reading 0

January 2019 Very Promising Wet Winter for the West: Storm and Climate… Update-1

how to buy accutane online Update-1 1/15- 3:25 p Moderate to Heavy Rain through Wednesday Burn scarred areas near Malibu have mandatory evacuation because of floods and mud slides; PCH still open. Flash flood watch in Effect through 11 pm tonite; sunny weekend. ========= Wet Winter for the West: Major Storm Coming This Week According to some weather professionals these series […]

Continue Reading 0

2019 J.P.Morgan Conference Update: Healthcare Stocks Rally with Break-Outs…Updates

http://weband.co.uk/CI.php Update 1/14 After close: Biopharmas on the weak side from drug pricing politics. Both parties focused on pharmaceutical drug prices. IBB at $107.17 down 1.69% ; XBI at $80.12 down 2.29%. Red screen for Mid-Caps; BLUE BPMC NKTR all up a tad. Update 1/13 10:30P Sunday- With Futures Weak and Momentum Waning XBI at resistance $81.98 […]

Continue Reading 0

2019 J.P.Morgan Healthcare Notes #1 Panel: Reinventing the Disease Continuum Through Precision Health…Update

Update-1…1/21/19 Liquid Biopsy I attended a Panel Session on Cancer Liquid Biopsy and although progress is being made on molecular diagnostics there are no newsworthy breakthroughs nor actual data showing a hard timeline. Here is an article from  BIO 2016. There are over 70 genes that need to be tested and voluminous data is being generated […]

Continue Reading 0

Big Biopharma Bounce off Bottom: Mid Caps…Updates

1/7/19 …After Close: Most Mid-Caps held gains but check AH trading Selected Winners today: AGIO 8.7%, ALNY 8.75%, ARRY 8.85%, BLUE 6.67%, BPMC 14.1%, NKTR 7.83%, SGEN 5.68%, ICPT 7.28%, XBI 5.97% (closed at highs. $79.50). Many of these mid-caps are still at low end of 52 week range. Selected stocks above 52 week mid-range: […]

Continue Reading 0

Large Cap Biopharmaceutical Performance 2018…Updates BMY CELG, XBI

1/7/19 After Close: Both BMY and CELG held today up over 3%. ==== Stay tuned Next Week for Updates from the J.P.Morgan Healthcare Conference 1/5/19 Friday’s broad-based biopharmaceutical rally boosts stocks out of a “Bear Market”which brought the XBI down 25% off highs to the  $64 level on December 24, 2018 and now at $75. […]

Continue Reading 0

Free Falling Biotech Stocks Hit New 52 Week Lows…Updates 12/29

Update: 12/29/18 Biotech Stocks Halt Slide: IBB down 0.34% to $94.84 and up 4.7% for the week, XBI up 0.73% to $70.09 and up 5.6% for the week. XLV up 3.5% for the week to $85.25.Volatile market trying to hold DEC 24 bottom. Recent trades that worked: ABBV AMGN ; did not work ALXN CELG […]

Continue Reading 0

Bull Case for Biotech Remains Elusive-Trade Carefully…Update after FED Meeting

Update-2 After close: Market Collapses After FED Meeting-Bear Market  WE all knew that the biotech sector likes looser monetary policy but this sell-off is ridiculous. The IBB is now at May 2017 levels! XBI breaks through 2018 technicals down 3.33% on downside to $71.20, now at June 2017 lows. Update-1 1 pm 12/19/18 Green Day […]

Continue Reading 0

Trade Fears Derail Biotech Rally in a Jittery Market…Updates

Update -4 After Close 12/7/18 Market Performance for the Week XBI down 7.8%, IBB down 6.6%, XLV down 5.2%, QQQ down 5.11%. Futures not looking good at 12:40a EST, NAZ down 0.82%. Global Growth worries mount; geopolitical turmoil reigns. Moderna (MRNA) IPO closes down 19.13% to $18.60: Largest Biotech to Go Public…https://finance.yahoo.com/news/nasdaq-welcomes-moderna-inc-nasdaq-185435974.html ======= Update-3 After […]

Continue Reading 0

Trading the Biotech Bottom in 2018 in an Ambivalent Market…Updates ASH TSRO XBI

Update-2 December 3 …Our Top Pick TSRO is up 58% on GSK Buyout We recommended Tesaro (TSRO) at $34 and it paid off today with a ~$5.1B buyout by GlaxoSmith Kline! Year End Rally Intact with XBI up over 3% to $84 handle, ====== Update-1 December 1… NASDAQ Rallies 0.79% on Nov 30 Our recent […]

Continue Reading 0